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Most HIV-infected individuals are coinfected by Herpes simplex virus type 2 (HSV-2). HSV-2 reactivates more frequently in
HIV-coinfected individuals with advanced immunosuppression, and may have very unusual clinical presentations, including




care providers should be aware that HSV-2 may cause atypical disease even in the context of near-complete immune reconstitution
on HAART.
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1. INTRODUCTION
Herpes simplex virus type 2 (HSV-2) is one of the most
prevalent sexually transmitted infections worldwide [1].
HSV-2 is extremely common in countries where HIV is
endemic,andcoinfectsover75%ofHIV-infectedindividuals
living in or originating from these countries, but the HSV-2
seroprevalence is also over 50% in HIV-infected individuals
from the developed world [2, 3]. Atypical or unusual
manifestations of genital herpes are not uncommon in HIV-
coinfected individuals, and persistent anogenital lesions due
to HSV-2 were among the ﬁrst opportunistic infections
described in those with the acquired immunodeﬁciency
syndrome (AIDS) [4]. Opportunistic infections may tran-
siently worsen during the period of immune reconstitution
followingtheinitiation ofhighlyactiveantiretroviraltherapy
(HAART), a phenomenon known as immune reconstitution
inﬂammatory syndrome (IRIS), with HSV-2 reactivation
accounting for up to half of IRIS cases [5]. However, the
median time from initiating HAART to developing IRIS
is three months, and IRIS is rare once stable immune
reconstitution has been achieved [5]. Antiviral-resistant
HSV is uncommon, although more frequently encoun-
teredamongimmunocompromisedindividuals comparedto
immunocompetent persons [6].
Hypertrophic anogenital lesions are a rare complication
of HSV-2 in HIV-coinfected men and women [7–10],
generally occurring in the context of signiﬁcant immune
deﬁciency or during IRIS [11], and these lesions may be
very diﬃcult to diagnose and treat. We present the case
of a 35 year-old, HIV-infected woman with a recalcitrant
hypertrophic vulvar lesion due to HSV-2. The development
and prolonged persistence of this lesion after near-complete
immune reconstitution on HAART implies that there are
signiﬁcant residual defects in host HSV-2 immune control,
and that these may have important clinical implications for
patients and their care providers.
2. CASE REPORT
The patient was a 34-year old, asymptomatic Zimbabwe-
born woman with a positive HIV IgG ELISA on immigration2 Infectious Diseases in Obstetrics and Gynecology
screening in 2002. There was no prior history of sexually
transmitted infections, genital or perianal ulceration, and
syphilis serology was negative. Her absolute CD4+ T cell
countatdiagnosiswas156/mm3,withanHIV-1RNAplasma
viral load of more than 100 000 copies/mL. Antiretroviral
therapy was initiated one month later, in October 2002,
with combivir one tablet twice daily and nevirapine 200mg
twice daily, together with trimethoprim/sulfamethoxazole
as primary prophylaxis against P. jiroveci pneumonia. By
January 2003, her CD4+ T cell count had increased to almost
500/mm3, and her HIV viral load remained persistently
undetectable after March 2003, at which point trimetho-
prim/sulfamethoxazole was discontinued. In April 2003,
she noted multiple painful papules on the left labia, with
subsequentsuperﬁcialulceration.Shehadnoreportedsexual
contacts for over a year. Her family physician prescribed
empiric therapy with acyclovir 400mg three times daily and
keﬂex 500mg three times daily, followed by oral valacyclovir
500mg twice daily.
In July 2003, nine months after starting HAART, the
shallow ulcerations had resolved but a pruritic 1 × 3cm
granulomatous lesion developed on the left labia. This
was associated with surrounding tissue edema, and shotty
left inguinal lymphadenopathy, and progressed over the
subsequenttwomonths(Figure 1(a)).Therewasnoresponse
to azithromycin 1 gram weekly for 4 weeks, as empiric
therapy for granuloma inguinale. Both a superﬁcial swab
and a punch biopsy of the hypertrophic lesion demonstrated
HSV-2, with glassy nuclear chromatin, multinucleation
and surrounding severe acute and chronic inﬂammation
(Figure 1(b)). Topical therapy was initiated with triﬂuridine,
together with oral valacyclovir 1 gram twice daily. There was
no clinical response, although valacyclovir discontinuation
was followed by an outbreak of painful, scattered shallow
ulcerations that were culture positive for HSV-2. From
November 2003 and December 2005 she was treated with 4
one-month courses of intravenous foscarnet; despite a near
total clinical response to the ﬁrst course, the response waned
progressively and the fourth course was complicated by
Staphylococcusaureuscellulitisatthelinesite. Lesioncultures
were repeatedly positive for HSV-2, and a repeat labial
biopsy in February 2006 showed only chronic granulation
tissue. There was no response to a trial of topical protopic
(tacrolimus) in August 2006.
In September 2006 there was a prompt clinical response
to topical imiquimod 5%, applied 3 times weekly, with
resolution of the lesion within eight weeks. She remains
asymptomatic on oral valacyclovir 1 gram twice daily com-
bined with topical imiquimod 5% as needed (approximately
one topical application every twoweeks) with minor residual
labial scarring.
3. DISCUSSION
We have presented a case of an African female patient with
recalcitrant hypertrophic genital HSV-2, which was clinically
resistant to standard antiviral therapy and to intravenous
foscarnet, but which responded promptly to topical 5%
imiquimod. An initial “typical” genital herpes outbreak
(a) Hypertrophic left labial lesion, two
months after initial occurrence (eleven
months after the initiation of antiretroviral
therapy)
(b) Photomicrograph of herpes-infected
cells from left labial biopsy, showing glassy
nuclear chromatin and multinucleation
(hematoxylin and eosin stain, 400 ×
magniﬁcation)
Figure 1: Clinical and microscopic appearance of hypertrophic
HSV-2 lesion.
occurred in the context of rapid immune recovery, and was
quite compatible with IRIS, as has been described in Ugan-
dan men starting therapy [11]. However, while this outbreak
responded to standard herpes therapy, the hypertrophic
genital HSV-2 lesion developed and persisted despite near-
complete immune recovery for up to three years. The rapid
clinical response that was seen to topical imiquimod, an
agonist of Toll-like receptor 7 (TLR7) that boosts both host
innateandadaptiveantiviralimmunity[12],stronglyimplies
thattherewereclinicallysigniﬁcantdefectsinhostantiherpes
immunity despite HAART-induced immune recovery.
Hypertrophic or squamoproliferative anogenital lesions
in HIV-positive individuals or those with AIDS are uncom-
mon and can pose a diagnostic dilemma. The most likely
causeofsuchlesionsiseitherneoplasiaorinfection,although
the diﬀerential diagnosis can be wide [13]. It may be diﬃcult
to determine the cause of a lesion based on appearance
alone, and the sensitivity of various diagnostic tests can
be aﬀected by the reactive changes present in these lesions
[10]. Further, small biopsies may be inconclusive or provide
misleading information [8]. It may be necessary to employ
repeat biopsies and viral cultures in cases suspicious for
HSV. In our patient, the ﬁrst biopsy of the lesion in 2003
was positive for HSV-2, but a second biopsy performed
after the lesion had recurred in 2006 was negative for HSV-
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immunohistochemical special stains, showing only chronic
granulation tissue present. This reinforces that it may be
diﬃcult to demonstrate virus even in a generous biopsy
specimen, especially in the presence of chronic, extensive
granulation tissue. Because this second biopsy was negative
for HSV, it is possible that HSV reactivation occurred within
this proliferative mass, rather than causing it. However, it
is more likely that HSV was in fact the etiologic agent
responsible for the progression.
The pathogenesis of proliferative and hypertrophic HSV
lesions in the immunocompromised patient population is
poorly understood. It is thought to be a reﬂection of the
increased duration of the disease course rather than any
inherent change in the pathogenicity of the HSV-2 itself
[14]. Early reports hypothesized that immune dysfunction
secondary to HIV, perhaps mediated by T-helper type 2
cytokines, might result in the epidermal hyperplasia [15].
Whatever the etiology of these lesions, their presence has
been linked to immune function. In HIV-infected individu-
als, HSV-2 infection is associated with an increased number
and size of genital lesions relative to immunocompetent
individuals [16]. Vesicles and ulcers are typically more
necrotic, painful, and heal more slowly [17]. Finally, as
CD4 cell count drops and immune status worsens, recurrent
outbreaks increase in frequency and severity [18].
Underlying the increased severity of HSV-2 disease
in HIV-coinfected patients are defects in herpes-speciﬁc
immunity.Inarecentreportofherpessimplexvegetansinan
HIV-infected individual with severe CD4+ T cell depletion
[19], a speciﬁc defect was demonstrated in the production
of type I interferons by plasmacytoid dendritic cells in
response to HSV. Dendritic cells within the epithelium of
the genital tract itself are important in mediating protective
immunity against HSV [20], but these cells are dramatically
depleted in the genital mucosa of HIV-infected individ-
uals [21]. Finally, HIV infection may be associated with
impaired HSV-2-speciﬁc CD8+ T cell responses, although
these defects improve progressively after starting HAART
[22]. In contrast, our patient had a normal CD4 count,
an undetectable viral load, and had been on HAART for
six months prior to the development of her lesions. The
pathogenesis of progressive hypertrophic HSV-2 in this
context, where such immune defects would be expected to
have improved substantially, is not clear, although a similar
case has been reported of a rapidly growing and recurrent
genital mass in an HIV-infected woman on HAART with a
CD4 T cell count >500/mm3 [7].
Immunocompromised individuals are more likely to be
infected with HSV-2 that is resistant to antiviral medica-
tions [6]. Resistance to acyclovir is usually associated with
resistance to the other nucleoside analog drugs, including
famciclovir and valacyclovir [9]. In such cases, foscarnet or
topical cidofovir may be useful, since they have diﬀerent
mechanisms of action [23]. Unfortunately, antiviral resis-
tance testing was not available for our patient, although
the prompt response of her “classical” ulcerative genital
herpes outbreak to both acyclovir and valacyclovir, with
rapid recurrence when suppressive treatment was stopped,
suggested drug sensitivity. However, the hypertrophic lesion
was clinically resistant to multiple courses of famciclovir
and valacyclovir, as well as to later courses of intravenous
foscarnet. Ultimately, there was a rapid and complete
response to topical 5% imiquimod cream. Others have
reported varied success with the use of imiquimod for HSV-
2 therapy [19, 24], and this drug should be considered
in the armamentarium for resistant and recurrent genital
HSV-2 in HIV-infected individuals. Thalidomide has also
been described as useful in HIV-positive patients with
hypertrophic lesions, although this drug was not used in our
case [25].
While uncommon, hypertrophic or squamoproliferative
HSV disease in the HIV-positive population can be a very
challenging clinical condition. It is painful, disﬁguring, and
diﬃcult to diagnose and treat. As demonstrated by our
patient, it can be seen in individuals anywhere along the
spectrum of immune dysfunction. If clinically suspected,
repeated attempts at diagnosis with viral cultures and
biopsies are warranted. These lesions are often resistant to
ﬁrst-lineantiviraltreatment,andmayrequirelesscommonly
used therapies such as foscarnet, cidofovir, imiquimod, or
thalidomide. In our case, imiquimod eventually resulted in
a good clinical outcome.
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